Author: Lucy Jean Sannes, Ph.D., M.B.A.
TABLES
Table 3.1: Valid Genomic Biomarkers in the Context of Approved Drug Labels 14
Table 3.2: Selected Companies Marketing Tests or Reagents for Detection of Genetic Variants of Cytochrome P450 [Not Including Warfarin Tests] 29
Table 3.3: Cytochrome P450 Drug Interaction Table - Clinically Relevant Drugs 34
Table 3.4: Selected Companies Marketing Tests or Reagents for Estrogen Receptor (ER) and Progesterone Receptor (PR) of Breast Tumor Tissue 40
Table 3.5: Selected Companies Marketing Tests or Reagents for Detection of HER2Overexpression 46
Table 3.6: Selected Companies Marketing Multi-Gene Tests for Determination of Breast Cancer Prognosis and Treatment 50
Table 3.7: Selected Companies Marketing Multi-Gene Tests for Other Cancers (Besides Breast Cancer) 56
Table 3.8: Selected Companies Marketing Tests for Determination of Over-Expression of Epidermal Growth Factor Receptor (EGFR) 62
Table 3.9: Selected Companies Marketing Tests for Determination of KRAS Variants 67
Table 3.10: Selected Companies Marketing Tests for Determination of BRAF 70
Table 3.11: Selected Companies Marketing Tests for Determination of UGT1A1 Variants 72
Table 3.12: Selected Companies Marketing Tests for Determination of DPYD and TYMS variants 73
Table 3.13: Selected Companies Marketing Tests for Biomarkers of Leukemia and Lymphoma 76
Table 3.14: Selected Companies Marketing Tests for Determination of Variants of the CYP2C9 and VKORC1 genes for Warfarin Sensitivity Testing 101
Table 3.15: Selected Companies Marketing Tests for Determination of Thiopurine Methyltransferase (TPMT) Mutations or Activity 104
Table 3.16: Selected Companies Marketing Personalized Medicine Tests for CNS Applications 105
Table 3.17: Selected Companies Marketing Other Personalized Medicine Drug/Diagnostic Combination Tests 108
Table 7-1: Research Programs and Diagnostic Tests in Development for Cancer Personalized Medicine 154
Table 7-2: Research Programs and Diagnostic Tests in Development for Other (Non-Cancer) Personalized Medicine, Plus Programs for Unspecified Disease Indications 171
Table 7.3: Selected Agreements Between Pharmaceutical/Biopharmaceutical Companies and Diagnostic Companies in Personalized Medicine 179
Commonly Available Pharmacogenetic Tests 188